Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors

CONCLUSION: PI may induce PAH in patients undergoing treatment, with Carfilzomib emitting a stronger signal than Bortezomib, and these patients should be monitored closely.PMID:38697649 | DOI:10.1183/13993003.02158-2023

Source: Respiratory Care - May 2, 2024 Category: Respiratory Medicine Authors: Julien Grynblat Charles Khouri Alex Hlavaty Xavier Jais Laurent Savale Marie Camille Chaumais Mithum Kularatne Mitja Jevnikar Ath énaïs Boucly Fabrice Antigny Fr édéric Perros G érald Simonneau Olivier Sitbon Marc Humbert David Montani French PH Netw Source Type: research